Graham Johnson

During an extensive medicinal chemistry career, Graham has held a number of senior leadership positions in biotech and large pharmaceuticals. These roles included: Senior Vice President, Preclinical Development and Research for AVI BioPharma (now Sarepta Therapeutics), Chief Research Officer for Rib-X Pharmaceuticals (now Melinta), Vice President of Bristol-Myers Squibb Discovery Chemistry for Connecticut and Canada, Director of Neuroscience Chemistry for Parke-Davis Pharmaceuticals, and CSO of Oricula Therapeutics. Graham has worked in such diverse areas as neuroscience, infectious and genitourinary diseases, inflammation and RNA therapeutics, is an inventor on more than 59 patents and has co-authored 70 peer-reviewed publications.

In addition to his responsibilities at Eleusis, Graham currently serves the medicinal chemistry needs of biotechnology companies, the National Institutes of Health, Venture Capital and Intellectual Property firms. Since its inception, Dr. Johnson has been a medicinal chemistry consultant to the Blueprint Neurotherapeutics Network (BPN). One of the first BPN programs generated the IP on which Oricula Therapeutics was founded.